Avalo Therapeutics, Inc.'s revenue has shrunk 85% a year over three years, and shrunk 61% a year over five. Revenue growth, 3-year annual rate: −85% (Biotechnology median +21%). Revenue growth, 5-year rate: −61%, growth has slowed since the five-year average. Years of annual history on file: 13, FY2013 to FY2025, as filed.

AVTXAvalo Therapeutics, Inc.

Healthcare

$6.93-56% 1Y

$6.93

$6.9352 weeks$22.87

Latest close: a new 52-week lowOct 23, 2026what changed →

Is it growing?

Is AVTX growing?

Avalo Therapeutics, Inc.'s revenue has shrunk 85% a year over three years, and shrunk 61% a year over five.

−85%

Revenue growth, 3-year annual rate · Biotechnology median +21% · shrinking · compounded from fiscal-year columns as filed

Revenue growth, 5-year rate: −61%
Revenue growth, 5-year rate · −85% over three · growth has slowed since the five-year average
Years of annual history on file: 13
Years of annual history on file · FY2013 to FY2025, as filed

Details›